Table 3 Summary table on median costs (interquartile ranges) in US dollars for TB and MDR-TB patients in the three study countries, related to costs for diagnosis, and treatment in the intensive phase and continuation phase
TB | MDR-TB | |||||
|---|---|---|---|---|---|---|
Ethiopia | Indonesia | Kazakhstan | Ethiopia | Indonesia | Kazakhstan | |
Direct pre(diagnosis) costs (costs in last 3 months) | 14 (4–109) | 33 (9–64) | 5 (1–13) | 68 (35–191) | 39 (12–63) | N.A.b |
Indirect pre(diagnosis) costs (costs in last 3 months) | 0 (0–30) | 4 (0–9) | 3 (1–5) | 0 (0–8) | 3 (1–6) | N.A.b |
Total pre(diagnosis) costs (costs in last 3 months) | 14 (6–129) | 35 (16–69) | 9 (4–19) | 75 (40–191) | 46 (16–82) | N.A.b |
Direct treatment costs | ||||||
Subtotal for intensive phase | 104 (10–231) | 41 (8–108) | 0 (0–74) | 639 (259–968) | 596 (342–1035) | 165 (0–541) |
Subtotal for continuation phase | 80 (34–156) | 59 (17–224) | 179 (90–328) | 634 (458–1048) | 976 (558–1584) | 754 (344–2022) |
Indirect treatment costs | ||||||
Intensive phase | 0 (0–34) | 10 (0–40) | 404 (303–674) | 220 (89–374) | 315 (153–848) | 1537 (0–2696) |
Continuation phase | 0 (0–4) | 9 (0–57) | 104 (70–159) | 73 (1–375) | 254 (0–504) | 227 (0–300) |
Total treatment costs | ||||||
Intensive phase | 119 (19–260) | 52 (17–134) | 607 (317–809) | 831 (462–1525) | 1079 (600–2299) | 1914 (175–3370) |
Continuation phase | 128 (34–177) | 82 (26–286) | 319 (236–702) | 931 (494–1296 | 1227 (730–1846) | 1202 (657–2245) |
Total (pre)diagnosis and treatment costsa | 260 | 169 | 929 | 1838 | 2342 | 3125 |